The government has suggested weight-loss drugs could boost the economy by helping obese people in England get back to work. But NHS experts have warned treatment services are already overstretched trying to deal with unprecedented demand from patients wanting these drugs.

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.

Popular weight loss drugs like Ozempic might be able to help with substance abuse, according to new research on people addicted to opioids and alcohol. Routine checkups for Brandon Downey, a South Jersey nurse who's taking Wegovy to lose weight, show a positive trend.

FDA approval: Ozempic is FDA-approved for Type 2 diabetes, while Wegovy is FDA-approved for weight loss. Cost: Ozempic is typically more affordable than Wegovy. At the time of publishing, the list price for Ozempic was $968.52 per month, whereas the list price for Wegovy was $1,349.02 per month. List prices are the price set by the manufacturer.

As for why it’s not approved for weight loss in the UK, Dr Kayat added: “It works by helping to regulate your appetite and reduce cravings and hunger. But in the UK, it’s only supposed to be used for type 2 diabetes, and that’s in order to try and protect the resources for the type 2 diabetics.”

In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and suicide attempts compared to adolescents who didn't.

Weight-loss drugs might help people battle addictions. Alcoholics taking GLP-1 drugs had a 50% lower rate of intoxication. Opioid users taking the drugs had a 40% lower risk of ov

A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds Ozempic, Wegovy, Mounjaro or Zepbound, may help users overcome alcoholism and opioid addiction.

Weight loss medications such as Ozempic may be able to cut drug and alcohol misuse in half, according to a new study from the scientific journal Addiction. The research, published Thursday, found that people who take Ozempic or similar drugs — those used for weight loss or treating Type 2 diabetes — were 40